Elixir Pharmaceuticals Sees IPO of 5 Million Shares at $14-$16 each
Dec 18 (Reuters) - Elixir Pharmaceuticals Inc, a company focused on drugs for metabolic diseases like diabetes and obesity, registered its initial public offering of 5 million shares at an estimated price of $14 to $16 per share.